Family office allocations to private equity fell from about 26% in 2023 to roughly 21% in 2025, the single largest allocation change of any asset class in the Goldman Sachs family office survey. The money did not disappear. It moved toward direct ownership of operating businesses and toward healthcare, which became the top thematic priority for family offices, with roughly 35% naming it a clear strategic focus in the UBS global family office report. The smartest patient capital in the world spent two years quietly walking away from the fund model and toward direct healthcare ownership. Ophthalmology sits exactly where those two moves intersect, which is why a family office that has already made both decisions is the most natural owner of a permanent-hold ophthalmology platform that exists.

Why Family Offices Think Differently About Ophthalmology

About 75% of family offices generated their original wealth from an operating business the family founded and ran, according to Goldman's survey work. That origin shapes everything about how they invest. They understand operating cash flow natively, because they lived inside it for years or decades before they had a family office at all. They know what it means to make payroll, to manage a margin, to grow a business slowly and own it outright. That experience makes them skeptical of the blind-pool fund that charges an annual fee and a slice of the profits to do something they already know how to do, which is own and run a business well.

When a family office that built its fortune on one great operating company looks at a fragmented, recession-resistant, demographically rising surgical specialty, it does not see a line item in someone else's fund. It sees the next great operating company, the kind of durable, cash-generating, ownable business that built the family's wealth in the first place. Ophthalmology speaks their native language because it is a business rather than a security. It has patients, surgeons, facilities, referral relationships, and recurring revenue, all of which a former operator can evaluate on instinct in a way they never could evaluate a fund's projected internal rate of return.

How the Ophthalmology Opportunity Fits the Direct-Investment Shift

The shift toward direct investing is partly a reaction to the same exit freeze that has trapped private equity. Family offices watched fund distributions slow to a trickle, watched financing costs rise, and watched their committed capital sit locked in vehicles that could not return it on schedule. They responded by preferring assets they could own and control directly, where they set the hold period and the decisions rather than waiting a decade for a fund manager to find an exit. A significant and growing share of family office alternative allocations now sits in direct investments rather than fund commitments, a deliberate move toward control and away from the blind pool.

Direct ownership of an ophthalmology platform with a clear successor-physician pipeline and surgical facility cash flow fits that preference precisely. It is controllable, it is understandable, and it does not depend on a fund manager finding a buyer in 2028. The family office can hold it for a generation, fund its growth from its own cash flow, and pass it down rather than marking it to a fund's liquidation schedule. For a family office that has already cut its private equity allocation and gone looking for direct healthcare exposure, the structure answers the exact question they were already asking, which is where to put patient capital that they control directly in a business they actually understand.

What the 5-Point Shift Signals for Ophthalmology Capital

A five-point allocation swing across the family office universe is not a rounding error. It represents a very large amount of capital changing direction, led by the investors with the longest time horizons and the least patience for fee drag. These are not investors chasing a trend. They are the slowest-moving, most deliberate capital in the market, and they moved toward direct healthcare ownership before most institutions noticed the shift was happening.

An ophthalmology platform built for permanent ownership is positioned in the exact lane the smartest patient capital already chose, ahead of the crowd that will eventually follow. The family offices already made the decision to cut private equity and own healthcare directly. The only remaining question is which platforms they choose to fund to execute that decision, and the platforms that share their philosophy of permanent ownership and physician-aligned structure are the ones that will speak to them when the conversation begins.

Why the Ophthalmology Time Horizon Matches Family Office Capital

What makes the fit unusually tight is the alignment on time horizon. A family office is often investing across generations, structuring holdings to pass from one generation to the next rather than to liquidate on a schedule. A permanent-hold ophthalmology platform is built to be owned indefinitely, funded from its own cash flow, and grown through a demographic wave that lasts longer than most investment horizons. The two are designed around the same assumption, which is that the best assets are the ones you never have to sell. A fund cannot offer that, because a fund is defined by its eventual liquidation. A permanent holder can, and a family office that built its wealth on a business it owned for decades recognizes the structure as a continuation of what already worked for them rather than a departure from it.

The skeptical version of this asks a fair question. If direct ownership of operating businesses is so obviously suited to family office capital, why has so much of it sat in private equity funds for so long? The answer is partly that funds offered access, diversification, and a manager to handle the work, which are real services a family office may not want to build in-house. The shift now underway is not a rejection of those services. It is a recognition that the fee load attached to them has grown difficult to justify against returns that matched the public market, and that for certain asset types, particularly fragmented operating businesses in sectors a family understands, direct ownership delivers more of the return to the owner. Ophthalmology is one of those asset types, which is why it surfaces precisely as the broader shift toward direct healthcare ownership accelerates.

The philosophical alignment is not a marketing flourish. It is the actual reason this category of capital is the right owner for this category of asset. A family office evaluating a permanent-hold ophthalmology platform is not being asked to learn a new asset class or trust an unfamiliar return profile. It is being shown a fragmented, cash-generating, recession-resistant operating business in a sector with a fifteen-year demographic tailwind, structured to be owned forever and funded from its own cash flow. That is the shape of the holding that built the family's wealth in the first place, offered again in a sector the data says is entering its best decade.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com